India carries the second largest burden of diabetes in the world. An estimated 77 million Indians have diagnosed diabetes — and a significant additional proportion have undiagnosed diabetes or pre-diabetic states that are equally capable of affecting health outcomes, including fertility and pregnancy. In a country where the condition is this prevalent, its intersection with fertility treatment is not a niche clinical consideration — it is an everyday clinical reality.
And yet the connection between diabetes and fertility is one that many couples undergoing fertility treatment have never had fully explained to them. They may have been told that their blood sugar is "a little high" and that they should watch their diet. They may have been diagnosed with PCOS without a full assessment of whether insulin resistance — the metabolic underpinning of PCOS and the continuum along which pre-diabetes and type 2 diabetes develop — is contributing to their infertility. They may have been through multiple IVF cycles without anyone asking whether glycaemic control before and during the cycles was optimal.
This article provides the complete explanation of how diabetes and fertility interact — in both women and men, across both type 1 and type 2 diabetes, and specifically in the IVF context. What the biological mechanisms are. What the specific impact on IVF outcomes is. And what optimizing metabolic health before and during IVF treatment involves.
The Diabetes Spectrum: From Insulin Resistance to Type 1
Before addressing the fertility implications, it is useful to clarify the range of conditions that the word "diabetes" encompasses — because the mechanisms and clinical implications differ meaningfully across the spectrum.
Insulin resistance — the physiological state in which cells respond less effectively to insulin, requiring the pancreas to produce more insulin to achieve the same glucose-lowering effect — is the common underlying mechanism of most type 2 diabetes and is closely associated with PCOS, obesity, and the metabolic syndrome. It exists on a continuum — from mild insulin resistance in a lean woman with PCOS to severe insulin resistance in an obese woman with impaired glucose tolerance.
Pre-diabetes — defined as fasting glucose between 100 and 125 mg/dL, or two-hour glucose between 140 and 199 mg/dL on a glucose tolerance test, or HbA1c between 5.7 and 6.4 percent — represents the state where insulin resistance is sufficient to elevate blood glucose above normal ranges without yet meeting the threshold for a diabetes diagnosis. Pre-diabetes has the same hormonal and inflammatory consequences as established diabetes — but at a degree that most clinical assessments outside fertility medicine do not flag as requiring active management.
Type 2 diabetes — the most common form, arising from progressive insulin resistance and eventual pancreatic beta-cell failure — is particularly relevant in the Indian fertility context because of India's disproportionately high rates of type 2 diabetes, its strong association with PCOS, and the younger age at which Indian populations tend to develop metabolic disease compared to Western populations.
Type 1 diabetes — an autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas, requiring exogenous insulin for survival — has distinct mechanisms and implications from type 2 diabetes, though both affect fertility and IVF outcomes through some shared and some distinct pathways.
Gestational diabetes — glucose intolerance developing during pregnancy — is relevant to fertility treatment because women who develop gestational diabetes in a pregnancy have an elevated risk of type 2 diabetes later in life, and because gestational diabetes itself carries implications for the pregnancy that IVF aims to establish.
How Diabetes Affects Female Fertility
The mechanisms through which diabetes and insulin resistance impair female fertility are multiple and interconnected.
Ovulatory Dysfunction Through Insulin-Androgen Interaction
Insulin resistance — whether in the context of PCOS, pre-diabetes, or type 2 diabetes — drives ovarian androgen excess through two mechanisms. Elevated insulin directly stimulates ovarian theca cells to produce androgens. And elevated insulin reduces sex hormone binding globulin (SHBG) — the protein that binds androgens and renders them biologically inactive — increasing the free (active) androgen concentration further. The resulting androgenic environment impairs the normal follicle development sequence, preventing any single follicle from reaching dominance and being released at ovulation.
This is the primary mechanism through which insulin resistance causes the anovulation of PCOS — and it operates identically in women who have insulin resistance without a formal PCOS diagnosis. A woman with pre-diabetes and irregular cycles but without the full Rotterdam criteria for PCOS may have her ovulatory dysfunction driven by the same insulin-androgen mechanism as a woman with formal PCOS — and may respond to the same metabolic interventions.
Egg Quality Impairment
Elevated blood glucose creates an environment of increased oxidative stress — reactive oxygen species produced by the non-enzymatic glycation of proteins and lipids — that is damaging to developing follicles and eggs. Studies consistently show that women with poorly controlled diabetes have lower fertilization rates, poorer embryo developmental quality, and higher aneuploidy rates than well-controlled diabetic or non-diabetic women at the same age and reserve level.
The mitochondria within the egg — the energy machinery that drives fertilization and early embryo development — are particularly sensitive to oxidative stress. Mitochondrial function in eggs from women with poorly controlled diabetes is impaired, and this impairment translates into reduced embryo developmental competence.
Endometrial Receptivity Impairment
The endometrium in women with insulin resistance and hyperinsulinaemia shows specific abnormalities of receptivity. The expression of endometrial receptivity markers — including integrins, pinopodes, and HOXA10, a gene critical for endometrial receptivity — is altered by elevated insulin and by the hyperandrogenic environment that insulin resistance creates. Multiple studies have demonstrated reduced implantation rates in insulin-resistant women compared to insulin-sensitive women with otherwise comparable fertility parameters.
Increased Miscarriage Risk
Poorly controlled diabetes — and to a lesser extent insulin resistance and pre-diabetes — is associated with elevated miscarriage rates. The mechanisms include the oxidative damage to egg and embryo quality described above, impaired endometrial receptivity, and in women with established diabetes, the systemic vascular and inflammatory effects of chronic hyperglycaemia.
The miscarriage risk associated with diabetes is modifiable — studies consistently demonstrate that improved glycaemic control before and during pregnancy reduces miscarriage rates toward those of non-diabetic women.
How Diabetes Affects Male Fertility
The male dimension of the diabetes-fertility connection is less discussed than the female dimension — and less frequently assessed. But it is real and clinically significant.
Oxidative stress and sperm DNA fragmentation. Elevated blood glucose creates the same oxidative stress in the male reproductive system that it creates in the ovarian follicle. Reactive oxygen species produced by chronic hyperglycaemia directly damage sperm DNA — elevating the DNA Fragmentation Index. Multiple studies have demonstrated higher sperm DNA fragmentation in men with type 2 diabetes compared to non-diabetic controls with comparable semen analysis parameters. And as established throughout this content library, elevated sperm DNA fragmentation impairs embryo developmental competence and implantation in ways that are entirely invisible to the standard semen analysis.
Sperm parameter impairment. Beyond DNA fragmentation, diabetes and insulin resistance are associated with reduced sperm count, reduced motility, and poorer morphology. The mechanisms include the Leydig cell dysfunction associated with the metabolic and hormonal disruption of diabetes, the scrotal temperature effects of obesity commonly accompanying type 2 diabetes, and the neuropathy and vascular changes of established diabetes that can impair ejaculatory function.
Erectile dysfunction and ejaculatory disorders. Established diabetic neuropathy and vasculopathy — complications of longstanding poorly controlled diabetes — can cause erectile dysfunction and retrograde ejaculation. These are not primarily fertility issues but are clinically relevant in couples where sexual dysfunction is contributing to infertility.
The Specific Impact on IVF Outcomes
When couples with diabetes — or with insulin resistance and pre-diabetic metabolic states — undergo IVF, the specific effects of metabolic dysfunction translate into quantifiable differences in IVF outcomes compared to metabolically normal patients.
Ovarian stimulation response. Women with insulin resistance and PCOS — the most common metabolic-ovarian combination in the Indian fertility context — produce a high antral follicle count but often develop follicles unevenly in stimulation, with multiple small follicles and reduced dominant follicle maturation relative to the follicle count. The ovarian hyperstimulation risk associated with PCOS is amplified by insulin resistance — the already reactive PCOS ovary responds more explosively to gonadotropin stimulation in an insulin-resistant metabolic environment.
Egg quality and embryo quality. As described above, hyperglycaemia and oxidative stress reduce egg quality and embryo developmental competence. Studies specifically in IVF populations have demonstrated lower fertilization rates, lower blastocyst formation rates, and poorer embryo morphology in women with poorly controlled diabetes or significant insulin resistance compared to metabolically normal women.
Implantation and clinical pregnancy rates. Reduced endometrial receptivity in insulin-resistant women translates into lower implantation rates per transferred embryo. Studies comparing implantation rates in insulin-resistant and insulin-sensitive PCOS women undergoing IVF demonstrate significantly lower implantation rates in the insulin-resistant group — a difference that is partially corrected by pre-cycle insulin-sensitization with metformin.
Miscarriage rates. Higher miscarriage rates in diabetic and insulin-resistant women undergoing IVF compound the reduced implantation rates — producing lower overall live birth rates per cycle than in metabolically normal women at the same age and reserve level.
What Metabolic Optimization Before IVF Involves
The clinical response to the diabetes-IVF connection at Metro IVF is comprehensive metabolic assessment and optimization before the IVF cycle begins — not a brief dietary recommendation, but a structured approach to ensuring that the metabolic environment in which the cycle takes place is as favorable as possible.
Glycaemic assessment. Every woman presenting for IVF evaluation at Metro IVF has fasting glucose and fasting insulin measured — along with HbA1c where indicated by clinical risk factors. These measurements identify insulin resistance, pre-diabetes, and established diabetes that may not have been previously diagnosed or adequately managed. The HOMA-IR calculation — derived from fasting glucose and fasting insulin — provides a practical estimate of insulin resistance degree that guides the need for intervention.
HbA1c target. For women with established diabetes undergoing IVF, an HbA1c below 6.5 percent — and ideally below 6.0 percent — is the pre-cycle optimization target. This target reflects the evidence that glycaemic control at this level significantly reduces miscarriage risk and improves IVF outcomes. For women whose HbA1c is above this target, IVF is deferred until glycaemic optimization is achieved — because the improvement in outcomes with better control is clinically significant, and the risks of proceeding with an unoptimized metabolic state include not only lower success rates but elevated pregnancy complication rates if the cycle succeeds.
Metformin. In women with insulin resistance, PCOS, or pre-diabetes, metformin — the insulin-sensitizing medication — is initiated before the IVF cycle if not already prescribed. As discussed in our PCOS article, metformin in insulin-resistant PCOS women improves ovulatory response, reduces androgen excess, and in the IVF context reduces the risk of OHSS by dampening the ovarian response to stimulation. For women with pre-diabetes outside the PCOS context, metformin also reduces the insulin-androgen disruption that impairs follicle quality.
Weight management. Obesity significantly amplifies insulin resistance and its fertility consequences. For women who are obese — particularly those with type 2 diabetes or pre-diabetes compounded by obesity — weight loss before IVF is one of the most impactful interventions available. A reduction of 5 to 10 percent of body weight consistently improves insulin sensitivity, reduces androgen excess, improves ovulatory function, and in multiple studies improves IVF success rates in obese women.
Dietary approach. A low-glycaemic index diet — reducing refined carbohydrates and high-sugar foods that produce sharp post-meal glucose and insulin spikes — is specifically relevant in the insulin-resistance and pre-diabetes context. This is not a calorie-restriction diet or a weight-loss programme per se. It is a dietary pattern that reduces the glycaemic load, reduces the insulin demand on the pancreas, and creates a hormonal environment more favorable to follicle development and endometrial receptivity.
Antioxidant supplementation. CoQ10, vitamin C, vitamin E, and N-acetylcysteine — antioxidants that reduce oxidative stress — are particularly relevant for women and men with diabetes or insulin resistance, where the chronic oxidative stress of hyperglycaemia amplifies the normal oxidative load. CoQ10 specifically supports mitochondrial function in eggs compromised by the metabolic environment.
Male partner management. For male partners with diabetes — particularly type 2 diabetes with insulin resistance — glycaemic optimization, antioxidant therapy, and lifestyle modification are equally important. Sperm DNA fragmentation testing is essential — because the elevated DFI associated with diabetes in the male partner is a potentially modifiable factor that antioxidant therapy and glycaemic improvement can address over a spermatogenesis cycle of approximately 70 days.
Type 1 Diabetes — Specific Considerations
Women with type 1 diabetes undergoing IVF face a somewhat different clinical picture from those with type 2 diabetes or insulin resistance.
Type 1 diabetes does not produce insulin resistance or androgenic excess — the mechanisms that most commonly impair fertility in the type 2 and metabolic syndrome context. Fertility in type 1 diabetes is primarily impaired by the direct effects of chronic hyperglycaemia on egg quality, by the autoimmune associations of type 1 diabetes (which include an elevated rate of other autoimmune conditions — thyroid autoimmunity, antiphospholipid syndrome — that independently affect fertility), and by the hypoglycaemic episodes that insulin-dependent management involves.
For women with type 1 diabetes, the pre-IVF optimization focuses on glycaemic stability — reducing both hyperglycaemia (which damages egg quality) and hypoglycaemia (which stresses the metabolic environment) — and on comprehensive autoimmune assessment, given the elevated rates of associated autoimmune conditions.
The IVF protocol for women with type 1 diabetes requires close coordination between the fertility team and the endocrinologist managing the diabetes — because the gonadotropin injections of ovarian stimulation produce significant hormonal changes that can alter insulin requirements, and the progesterone supplementation of the luteal phase has an insulin-antagonizing effect that requires dosage adjustment in insulin-dependent patients.
The Practical Message
The connection between diabetes and fertility — from insulin resistance in PCOS through pre-diabetes to established type 1 and type 2 diabetes — is real, clinically significant, and in most cases partially or substantially modifiable before IVF treatment begins.
The modifications that matter most are the straightforward ones: glycaemic assessment in every fertility patient, HbA1c optimization to below 6.5 percent in diabetic women before IVF, metformin for insulin-resistant patients, dietary adjustment toward low glycaemic index eating, and antioxidant supplementation for both partners.
These interventions are not complex. They are not expensive. They are, in a substantial proportion of couples, significantly underutilized — because the fertility evaluation that precedes IVF at many clinics does not include the metabolic assessment that would reveal the need for them.
At Metro IVF, the metabolic assessment is routine. The optimization is systematic. And the IVF cycle that follows benefits from a metabolic environment that has been prepared for it — not one in which glycaemic dysfunction is silently impairing every stage of the process from egg quality to embryo development to implantation.
Your Next Step
If you have diabetes — or have been told that your blood sugar is "a little high," or have PCOS with significant insulin resistance — and are considering IVF, a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur will give you the most complete metabolic assessment and the most individualized pre-IVF optimization plan available.
The metabolic environment of your IVF cycle matters. Getting it right before the cycle begins is one of the most important things you can do for its success.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Metabolic health is fertility health. Book your consultation with Dr. Ashish Soni at Metro IVF today — and prepare your body for the IVF cycle it deserves.